Norges Bank
MRKR icon

Norges Bank’s Marker Therapeutics MRKR Stock Holding History

Norges Bank’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-44,340
Closed -$421K – 2212
2021
Q4 		$421K Sell
44,340
-13,580
-23% -$180K ﹤0.01% 2154
2021
Q3 		$979K Buy
+57,920
New +$1.19M ﹤0.01% 2149

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
AAM
AR Asset Management West Hollywood, California $517M AUM 18.31% 1-Year Est. Return

Norges Bank's MRKR Position: Q1 2022 in Review

Norges Bank sold out of Marker Therapeutics (MRKR) in Q1 2022, closing a stake of 44,340 shares — an estimated $421K sold.

Norges Bank first reported a position in MRKR in Q3 2021 and held it in 2 quarters. The position peaked at $979K in Q3 2021. 49 funds tracked by Wall St. Rank hold MRKR as of Q1 2022.

  • Norges Bank reported no remaining Marker Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Norges Bank sold 44,340 Marker Therapeutics shares in Q1 2022, an estimated $421K.
  • Norges Bank first reported a position in Marker Therapeutics in Q3 2021 and held it in 2 quarters.
  • Norges Bank's Marker Therapeutics position peaked at $979K in Q3 2021.
  • 49 funds tracked by Wall St. Rank held Marker Therapeutics as of Q1 2022.

Based on Norges Bank's 13F filing for Q1 2022, filed 9 May 2022.